ADC Therapeutics SA USD 200 million private placement

On 23 October 2017, ADC Therapeutics SA, an oncology drug discovery and development company that specializes in the development of Antibody Drug Conjugates (ADCs) targeting major cancers, announced that it has raised USD 200 m through a private placement of shares. According to, the placement is the fourth largest private financing round on record for a European biopharmaceutical firm and the second largest private equity round in European biopharma so far in 2017.